The study found that the KRAS gene-driven lung cancer ICI treatment response rate was the highest at 26%, followed by BRAF, with a response rate of 24%, and the MET-driven lung cancer ICI response rate was 16%, which were relatively higher than those of other driver genes [30]. This evidence concerns the gene KRAS and lung carcinoma.